Drug intelligence / Profile preview

trastuzumab-AJICAP-MMAE

Development stage: Preclinical
Lead developer: Ajinomoto
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Trastuzumab-AJICAP-MMAE is a site-specific antibody-drug conjugate (ADC) developed by Ajinomoto using their proprietary AJICAP (Fc-affinity guided chemical conjugation) technology. The drug consists of the anti-HER2 monoclonal antibody trastuzumab (Herceptin) conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valine-citrulline (MC-VC) linker. The conjugation occurs at a specific lysine residue (Lys248) in the Fc region of the antibody, resulting in a drug-to-antibody ratio (DAR) of approximately 1.6 to 2.0. This site-specific approach aims to improve the therapeutic index and pharmacokinetic profile compared to traditional stochastic ADCs by reducing heterogeneity. Preclinical studies in HER2-positive gastric cancer xenograft models and rat toxicology studies have demonstrated potent anti-tumor activity and a favorable safety profile.

Other names: AJICAP-ADCtrastuzumab-MMAE ADC (AJICAP)

Targets

TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on trastuzumab-AJICAP-MMAE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trastuzumab-AJICAP-MMAE.

Explore the full profile